TOUCHSTONE SANDS CAPITAL SELECT GROWTH FUND CLASS A (TSNAX US) stock market data APIs
18.1038
0(0%)
as of July 3, 2025
Try our APIs with
free plan!
TOUCHSTONE SANDS CAPITAL SELECT GROWTH FUND CLASS A Financial Data Overview
Price chart is built with
Anychart
Prev. Close
18.1038
Open
18.1038
High
18.1038
Low
18.1038
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TOUCHSTONE SANDS CAPITAL SELECT GROWTH FUND CLASS A data using free add-ons & libraries
End-of-day & Earnings data
Get TOUCHSTONE SANDS CAPITAL SELECT GROWTH FUND CLASS A Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get TOUCHSTONE SANDS CAPITAL SELECT GROWTH FUND CLASS A End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TOUCHSTONE SANDS CAPITAL SELECT GROWTH FUND CLASS A News
New
New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma
- Separate analyses provide insight into the characteristics of patients who respond long-term and management of drug-related rash - Posters presented at the 62nd American Society of Hematology (ASH)...
New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma
- Separate analyses provide insight into the characteristics of patients who respond long-term and management of drug-related rash - Posters presented at the 62nd American Society of Hematology (ASH)...
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia-- --Exhibitor Spotlight presentation highlights advances in th...
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia-- --Exhibitor Spotlight presentation highlights advances in th...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
